Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier B. Groth CG, et al. Among authors: morales jm. Transplantation. 1999 Apr 15;67(7):1036-42. doi: 10.1097/00007890-199904150-00017. Transplantation. 1999. PMID: 10221490 Clinical Trial.
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P. Kreis H, et al. Among authors: morales jm. Transplantation. 2000 Apr 15;69(7):1252-60. doi: 10.1097/00007890-200004150-00009. Transplantation. 2000. PMID: 10798738 Clinical Trial.
Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
Ruiz JC, Campistol JM, Grinyó JM, Mota A, Prats D, Gutiérrez JA, Henriques AC, Pinto JR, García J, Morales JM, Gómez JM, Arias M. Ruiz JC, et al. Among authors: morales jm. Transplantation. 2004 Nov 15;78(9):1312-8. doi: 10.1097/01.tp.0000137322.65953.0a. Transplantation. 2004. PMID: 15548969 Free article. Clinical Trial.
Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients.
Claesson K, Mayer AD, Squifflet JP, Grabensee B, Eigler FW, Behrend M, Vanrenterghem Y, van Hooff J, Morales JM, Johnson RW, Buchholz B, Land W, Forsythe JL, Neumayer HH, Ericzon BG, Mühlbacher F. Claesson K, et al. Among authors: morales jm. Transplant Proc. 1998 Jun;30(4):1292-4. doi: 10.1016/s0041-1345(98)00246-2. Transplant Proc. 1998. PMID: 9636524 Clinical Trial. No abstract available.
Is nonnephrotoxic immunosuppression a possibility?
Bäckman L, Morales JM. Bäckman L, et al. Among authors: morales jm. Transplantation. 2000 Jun 27;69(12 Suppl):SS27-30. doi: 10.1097/00007890-200006271-00007. Transplantation. 2000. PMID: 10910261 Review. No abstract available.
Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
Squifflet JP, Bäckman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, Kunzendorf U, Heemann U, Land W, Morales JM, Mühlbacher F, Talbot D, Taube D, Tyden G, van Hooff J, Schleibner S, Vanrenterghem Y; European Tacrolimus-MMF Renal Study Group. Squifflet JP, et al. Among authors: morales jm. Transplantation. 2001 Jul 15;72(1):63-9. doi: 10.1097/00007890-200107150-00014. Transplantation. 2001. PMID: 11468536 Clinical Trial.
514 results